HHCCI fosters the development of cutting-edge, innovative, collaborative studies focused on the prevention, detection, diagnosis and treatment of cancer in a responsible way. Our aim is to minimize the time and resources needed to move trials from concept development to patient enrollment
Research Leadership Council
The Research Leadership Council steers research program growth and direction to maximize research’s impact on the delivery of quality care to the communities we serve. As such, the Council:
- Establishes research program goals and strategic priorities
- Aligns program strategy with institutional goals and drives system-wide progress
- Provides oversight of the self-directed Disease Management Teams
- Monitors program performance and financial health
- Oversees safety and quality
- Identifies resolution pathways to complex challenges
Protocol Evaluation and Management Committee (PEMC)
The PEMC is charged with steering the HHCCI clinical research portfolio through careful protocol selection and ongoing monitoring. PEMC membership is multi-disciplinary and includes representation from all HHC regions engaged in research.
Interventional, ancillary and correlative protocols are initially evaluated for resource feasibility within respective Disease Management Teams and submitted to the PEMC for review. The PEMC prioritizes studies aligned with the HHCCI mission that have the highest likelihood of success and represent the best use of network resources. All vetted protocols are tracked through the CCRO Study Startup Unit.
Email us to submit a study for PEMC review or request more information.
Disease Management Teams (DMTs)
Multidisciplinary DMTs are composed of physicians and healthcare professionals such as medical oncologists, surgical oncologists, radiation oncologists and nurses who are experts in their field. DMTs discuss standards of care and emerging literature while evaluating clinical research opportunities, studies and participants. Each DMT physician research lead works closely with the research ambassadors (clinical research coordinator or research nurse) to identify, develop and maintain a portfolio of high-quality cancer studies within a disease group that promotes and supports the HHCCI mission.
Each DMT is responsible for reviewing proposed studies for scientific interest, community impact, feasibility, the ability to enroll, and priority within the disease-specific portfolio. Protocols approved by the DMT are submitted to the Protocol Evaluation Management Committee for review and approval before a study can start.
- Breast
Patricia DeFusco, MD
- Cardio-Oncology
Eric Oligino, MD
- Gastrointestinal
Gerartd Funo, MD
- Genitourinary
Anoop Meraney, MD
- Gynecologic Oncology
Jonathan Cosin, MD
- Hematology
Mark Daiely, MD
- Head & Neck
Casey Kuwada, MD
Akshay Patel, MD
- Lung
Wylie Hosmer, MD
- Neuro-Oncology
Ahmad Daher, MD
- Hepatobiliary & Pancreatic
Bret Schipper, MD
- Sarcoma
Adam Lindsay, MD
- Cutaneous Malignancies
Omar Eton, MD\
Organizational structure
Physician leaders and research professionals are organized in a way that maximizes our resources, ensures efficiency and delivers an excellent patient experience.